Paper Details

  1. Home
  2. Paper Details

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

Author: , BoninoFerruccio, ButtonPeter, DiagoMoises, FarciPatrizia, GermanidisGeorgios, GurelSelim, HadziyannisStephanos, JinRui, LaiMing-Yang, LauGeorge K K, LuZhi-Meng, MarcellinPatrick, PiratvisuthTeerha, PluckNigel, YurdaydinCihan

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Current treatments for chronic hepatitis B in people who don’t have a specific type of the virus (HBeAg-negative) often don’t lead to a lasting response. As a result, antiviral medications are often taken indefinitely, which can lead to resistance and unknown long-term side effects.
Paper Details　
Original Abstract of the Article :
Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety impl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15371578

データ提供：米国国立医学図書館（NLM）

New Treatment Strategies for Chronic Hepatitis B: A Focus on HBeAg-Negative Patients

Hepatitis B is a serious liver infection, and finding effective treatments is vital for preventing long-term complications. This research explores treatment strategies for patients with HBeAg-negative chronic hepatitis B, a specific subtype of the disease associated with challenges in achieving sustained responses. The study highlights the limitations of existing treatment options, emphasizing the need for new and more effective approaches for managing this form of hepatitis B.

What does this research tell us?

This research underscores the need for improved treatment options for patients with HBeAg-negative chronic hepatitis B. The study highlights the limitations of current therapies and emphasizes the urgency of developing new strategies to address the specific challenges faced by these patients.

Looking at the bigger picture: what does this mean for your health?

If you are living with chronic hepatitis B, it is crucial to work closely with your healthcare provider to manage your condition effectively. They can monitor your liver health, discuss treatment options, and provide personalized guidance for managing your condition. It is also important to stay informed about ongoing research and potential advancements in hepatitis B treatments.

Dr. Camel's Conclusion

This research, like a camel traversing the vast desert in search of a water source, highlights the need for new and effective treatments for HBeAg-negative chronic hepatitis B. It reminds us that the journey towards better health outcomes for those living with this condition is ongoing, requiring constant exploration and innovation.

Date :
  1. Date Completed 2004-09-21
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

15371578

DOI: Digital Object Identifier

351/12/1206

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.